FDA Considers MDMA as Breakthrough Therapy for PTSD

The US Food and Drug Administration (FDA) has been asked to review MDMA, the active ingredient in street drugs like ecstasy and molly, along with therapy as a potential treatment for post-traumatic stress disorder (PTSD). The application was filed by the MAPS Public Benefit Corporation, which has been studying the drug in combination with therapy. MDMA has shown promising results in reducing symptoms and impairment associated with PTSD in clinical trials. If approved, MDMA would need to be rescheduled as it is currently classified as a schedule I drug with no accepted medical use.